Communications with public office holders regarding policies, regulations and programs affecting pharmaceutical pricing and reimbursement frameworks, including the Patented Medicine Prices Review Board (PMPRB), international reference pricing approaches, most-favoured-nation pricing policies and their impacts on investment, innovation, market access and the availability of medicines and health technologies in Canada. Communications with public office holders regarding policies and initiatives to encourage trade between Canada and the United States, including with regard to the United States-Mexico-Canada Agreement (USMCA).